药物相互作用的临床试验数据驱动风险评估:一个快速而准确的决策工具
Tong Yuan1, Fulin Bi1, Kuan Hu1
1Key Laboratory of Drug Metabolism and Pharmacokinetics, School of Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang Rd, Nanjing, 210009, People's Republic of China.
Clinical pharmacokinetics
|August 5, 2024
概括
这项研究引入了评估药物相互作用 (DDI) 的新工具,通过考虑抑制剂功效和基质代谢. 开发的临床DDI风险尺度准确预测了相互作用风险,有助于安全的药物治疗实践.
科学领域:
- 药理动力学和药物新陈代谢
- 临床药理学 临床药理学
- 计算的药物相互作用预测.
背景情况:
- 目前的临床药物相互作用 (DDI) 评估由于不完全考虑关键因素而缺乏准确性.
- 现有的方法通常依赖于从临床试验数据的基本推断,忽视抑制剂的功效,剂量,基质代谢和肠道可用性.
研究的目的:
- 开发一个高效和准确的临床工具来评估药理学介导的DDI.
- 将抑制剂的强度,剂量,基质代谢分数和肠道可用性全面纳入DDI结果预测中.
主要方法:
- 专注于细胞染色体P450 3A4酶介导的DDI,利用临床试验数据计算基质代谢分数和肠道可用性.
- 开发了一种方法来确定抑制剂度和强度 (或),并预测了33种基质和20种抑制剂的DDI结果.
- 使用基质风险和抑制剂强度指数建立了临床DDI风险尺度,通过89项临床DDI试验验证.
主要成果:
- 在体内计算的和值与其他方法相比显示出更高的可靠性,几何平均折叠误差和根平均平方误差较低.
- 基于生理学的药理动力学-DDI建模显示,当基质代谢酶被抑制时,C-t曲线的适合性很好.
- 在81%的案例中,曲线比率预测下的区域在1.5×误差范围内,81%的案例中,DDI风险尺度表现出较低的假负率 (5.6%).
结论:
- 已开发出一种快速而准确的方法,用于在临床环境中评估药理学介导的DDI.
- 该工具为在临床实践中合理使用药物组合和精确剂量调整提供了基础.
相关概念视频
01:19Pharmacovigilance
801
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
801
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
124
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
124
01:12Hazard Ratio
106
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
106
01:29Drug-Receptor Interactions
5.1K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.1K
01:14Agonism and Antagonism: Quantification
335
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
335